BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16457285)

  • 1. [Immunohistochemical analysis for cholangiocarcinoma].
    Nakagoe T; Matsuo T; Kondoh M; Yamaguchi H
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():370-4. PubMed ID: 16457285
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tumor markers in the diagnosis of tumors in the subhepatic area].
    Dufek V; Petrtýl J; Klener P; Chmel J
    Vnitr Lek; 1994 Jun; 40(6):350-3. PubMed ID: 8073643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
    Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor markers for ovarian cancers].
    Aoki D; Kataoka F; Susumu N; Nozawa S
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():496-502. PubMed ID: 15535295
    [No Abstract]   [Full Text] [Related]  

  • 5. [A case of intrahepatic cholangiocarcinoma with marked high levels of CEA, AFP and CA 19-9].
    Tanigawa T; Takagi S; Suga K; Morikawa Y; Hotta T; Haruyama H; Kusaba A; Akashi K; Nishida K; Miyazaki T
    Nihon Naika Gakkai Zasshi; 1987 Jan; 76(1):138-41. PubMed ID: 2437230
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cathepsin B-like substance in the monitoring of chemically induced primary cholangiocarcinoma in swine].
    Dufek V; Petrtýl J; Klener P
    Vnitr Lek; 1996 Aug; 42(8):551-4. PubMed ID: 8967025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
    Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
    Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoplasm markers useful for diagnosis and monitoring of colonic neoplasms].
    Ławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw; 2002; 56(5):617-34. PubMed ID: 12596691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and bile markers for cholangiocarcinoma.
    Nehls O; Gregor M; Klump B
    Semin Liver Dis; 2004 May; 24(2):139-54. PubMed ID: 15192787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up.
    Charatcharoenwitthaya P; Lindor KD
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):32-6. PubMed ID: 17234554
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
    Dong H; Cong WL; Zhu ZZ; Wang B; Xian ZH; Yu H
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
    Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K
    Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirizzi's syndrome with a high CA19-9 level mimicking cholangiocarcinoma.
    Lin CL; Changchien CS; Chen YS
    Am J Gastroenterol; 1997 Dec; 92(12):2309-10. PubMed ID: 9399781
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
    Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
    J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The value of CA19-9 in diagnosing hepatocellular carcinoma and intrahepatic cholangiocarcinoma].
    Chen Y; Wang ZM; Ren ZG; Le F; Zhang BH; Xia JL; Ye SL; Tang ZY
    Zhonghua Gan Zang Bing Za Zhi; 2006 Apr; 14(4):299-300. PubMed ID: 16635306
    [No Abstract]   [Full Text] [Related]  

  • 16. [Tumor markers in biliary tract cancer].
    Najima M; Okusaka T
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():419-21. PubMed ID: 16457296
    [No Abstract]   [Full Text] [Related]  

  • 17. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
    Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
    Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor marker and its clinical significance in diagnosis of colorectal cancer].
    Imai Y
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():193-6. PubMed ID: 14574880
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
    Li YG; Zhang N
    Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
    Patel AH; Harnois DM; Klee GG; LaRusso NF; Gores GJ
    Am J Gastroenterol; 2000 Jan; 95(1):204-7. PubMed ID: 10638584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.